IRE - Institute for radioelements

What we do: The Institute for Radioelements (IRE) is a public utility foundation specializing in the production of radioisotopes used in nuclear medicine for diagnostic and therapeutic purposes. Its products serve as active ingredients in many radiopharmaceutical medicines. IRE is a global leader in producing molybdenum-99, the parent isotope of technetium-99m, widely used in medical imaging for organs such as the heart, bones, lungs, thyroid, brain, and kidneys. Its subsidiary, IRE ELiT, develops radiopharmaceutical derivatives for cancer treatment and palliative care, and also conducts radiological monitoring of Belgium through its radioactivity measurement laboratory. Additionally, IRE ELiT engages in international projects related to radioactivity characterization and business development.

Where we are located: IRE's headquarters are located at Avenue de l’Esperance 1, 6220 Fleurus, Belgium. The company operates primarily from this site, which also hosts its subsidiary IRE ELiT.

Short history: Founded as a public utility foundation, IRE has established itself as a world leader in radioisotope production, particularly molybdenum-99. IRE ELiT was created in 2010 as an innovation subsidiary to expand diagnostic and therapeutic radiopharmaceutical applications. The company has continuously invested in research and development, dedicating over 16% of its turnover to R&D as of 2017, and has recently expanded its production capacity with strategic investments such as the installation of a 30 MeV cyclotron in 2024.

Organization & culture: IRE employs over 260 people, with IRE ELiT employing more than 40 staff members. The company values excellence in nuclear medicine, healthcare, and environmental safety. Its culture is shaped by strong moral principles guiding its activities, emphasizing innovation, quality, and commitment to patient care and environmental monitoring.

Recent developments: In December 2024, IRE installed a new 30 MeV IBA cyclotron at its Fleurus site to enhance production capabilities, particularly for germanium-68. Additionally, IRE collaborates with the Belgian Nuclear Research Centre (SCK CEN) to begin large-scale production of lutetium-177, a promising radioisotope for cancer treatment, including prostate cancer.